Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Study population We included all patients registered as having type 2 diabetes in the National Diabetes Register who filled their first prescription for a GLP-1 receptor agonist, and, in a separate cohort, all patients registered as having type 2 diabetes in the National Diabetes Register who filled their first prescription for an SGLT2 inhibitor, between 1 January 2017 and 31 December 2021 (ensuring a minimum of 1-year follow-up until the end of the study period on 31 December 2022)
Accessed April 23, 2026
This partnership with Noom will empower the people we serve to take charge of their health through healthier habits and weight management to mitigate chronic conditions, and were excited to see the benefits it brings to our members, said Mach McGee, Vice President and Chief Marketing Officer of CareFirst
Sluis, van J.M
Recently, the Wegovy pill, an oral semaglutide option, was approved by the FDA, providing more choices for those who prefer not to inject
